Medical device company Prytime Medical Devices Inc, a provider of minimally invasive solutions for haemorrhage control, stated on Tuesday that it has raised USD6m from its inside financing round.

Prytime Medical said it will use the oversubscribed funding round to support the commercialization of of minimally invasive REBOA (Resuscitative Endovascular Balloon Occlusion of the Aorta) haemorrhage control products as well as shift its commercial focus simply product familiarisation towards deep customer support and quality clinical outcomes.

The company added that its growth is based on experience from over four years of market engagement and 7500 clinical uses worldwide.

According to Prytime Medical, pREBOA-PRO is the first US FDA-cleared REBOA catheter designed specifically for true partial REBOA, not just intermittent REBOA like other devices. The company's latest innovations, the industry leading ER-REBOA PLUS and the innovative pREBOA-PRO partial REBOA Catheter, enable truncal haemorrhage control and simultaneously more controlled resuscitation in a much wider range of clinical scenarios.